Fitbit’s Final Days?
Fitbit cuts guidance after its latest quarterly report and shares hit an all-time low. Aaron Bush analyzes the lone bright spot on Fitbit’s balance sheet, but this may be the beginning of the end. Shares of data analytics software company Alteryx rise another 10%, while shares of medical device maker Abiomed fall more than 20%. Plus, we discuss the current landscape of esports and potential investments in this growing industry.